RNA interference (RNAi) provides researchers with a versatile means to modulate target
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …

Abstract Purpose of Review The aim of creating an orally active non-statin cholesterol-
lowering drug was achieved with bempedoic acid, a small linear molecule providing both a …

Dyslipidaemia is a well-known risk factor for the development of cardiovascular disease, a
leading cause of morbidity and mortality in developed countries. As a consequence, the …

Inclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA
(siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 …

Low-density lipoprotein cholesterol (LDL-C) plays a crucial role in the development of
atherosclerosis. Statin therapy is the standard treatment for lowering LDL-C in primary and …

Background: Statins have emerged as a vital therapeutic option for dyslipidemia, effectively
reducing morbidity and mortality in individuals with various medical conditions. Recent …

RNA interference has become increasingly used for genetic therapy following the rapid
development of oligonucleotide drugs. Significant progress has been made in its delivery …

Introduction Bempedoic acid (BA) has shown significant progress in reducing cholesterol
levels and is relatively free from the many side effects encountered with the use of other …

The aim of the work is a literature review of published clinical studies on the effects of
hyperuricemia on the course of chronic heart failure (CHF). Results. High levels of uric acid …

Hyperlipidemia is a medical condition characterized by high levels of lipids in the blood. It is
often associated with an increased risk of cardiovascular diseases such as heart attacks and …